Lab services specialist SourceBio International PLC (AIM:SBI) hailed the ‘exceptionally strong’ market demand for cellular pathology in an update ahead of its annual meeting later Wednesday.
A continued shortage of pathologists coupled with the increasing momentum of elective surgeries coming back provided the impetus.
SourceBio also said March’s £18.5mln acquisition of LDPath, a digital pathology testing services group, had proved ‘very favourable’, given this backdrop.
The integration of the new operation is ‘progressing well’, investors were told.
The company said the genomics business had enjoyed a ‘healthy’ start to 2022, while it said it planned to further grow its ‘highly profitable’ stability storage unit.
“We continue to invest organically and pursue strategically relevant and earnings-enhancing acquisitions to augment the growth of these core business units and to further strengthen our capabilities and offerings to customers,” SourceBio said.